Drug details

Lithobid (lithium carbonate tablets)

type of Bipolar Disorder Agents

Lithobid (lithium carbonate) Extended-Release is an alkali-metal indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-IV) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithobid is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur.

The drug is often used to treat Bipolar disorder .

This drug may have the following side effects:

• nausea
• diarrhea
• vomiting
• drowsiness
• Lack of coordination
• hand tremor
• increased dilute urination
• mild thirst
• muscular weakness, and

The following drugs are related to Lithobid, either as a replacement or used together:

• Saphris (asenapine sublingual tablets)
• Rexulti (brexpiprazole tablets)
• Celexa (citalopram hydrobromide)
• Lexapro (escitalopram oxalate)
• Lamictal (lamotrigine)
• Lamictal XR (lamotrigine extended-release tablets)
• Latuda (lurasidone hcl tablets for oral administration)
• Zyprexa (olanzapine)
• Zyprexa Relprevv (olanzapine extended release injectable suspension)
• Trileptal (oxcarbazepine)
• Risperdal (risperidone)
• Risperdal Consta (risperidone)
• Zoloft (sertraline hcl)
• Trokendi XR (topiramate extended-release capsules)